ポナチニブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ポナチニブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

5nih.gov

4^th place

24^th place

3doi.org

2^nd place

6^th place

2otsuka.co.jp

low place

3,121^st place

2medpagetoday.com

9,274^th place

low place

1iclusig.com

low place

1fda.gov

447^th place

1,043^rd place

1nytimes.com

7^th place

63^rd place

1pmda.go.jp

6,690^th place

394^th place

1onclive.com

low place

1fiercebiotech.com

low place

1ariad.com

low place

1clinicaltrials.gov

5,225^th place

low place

ariad.com

investor.ariad.com

“ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia”. 2013年10月18日閲覧。

clinicaltrials.gov

“Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia”. 2023年9月20日閲覧。

doi.org

“Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant”. J. Med. Chem. 53 (12): 4701–19. (June 2010). doi:10.1021/jm100395q. PMID 20513156.
“AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance”. Cancer Cell 16 (5): 401–12. (November 2009). doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.
“Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance”. Chemical Biology & Drug Design 77 (1): 1–11. (January 2011). doi:10.1111/j.1747-0285.2010.01054.x. PMID 21118377.

fda.gov

“FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales”. FDA Drug Safety Communication. U.S. Food and Drug Administration (2013年10月31日). 2013年11月3日閲覧。

fiercebiotech.com

Carroll J. “UPDATED: Ariad hammered on toxicity concerns for leukemia drug Iclusig”. FierceBiotech. 2021年9月18日閲覧。

iclusig.com

“Iclusig (ponatinib) Tablets, for Oral Use. Full Prescribing Information”. ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street, Cambridge, MA 02139-4234. 2 October 2016閲覧。

medpagetoday.com

Gever J (Dec 14, 2012). “Ponatinib Wins Early FDA Nod”. Oncology/Hematology. MedPageToday.com. 2021年9月18日閲覧。
Gever J (Dec 10, 2012). “Ponatinib Retains Luster in Leukemia”. Oncology/Hematology. MedPageToday.com. 2021年9月18日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant”. J. Med. Chem. 53 (12): 4701–19. (June 2010). doi:10.1021/jm100395q. PMID 20513156.
“AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance”. Cancer Cell 16 (5): 401–12. (November 2009). doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.
“Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance”. Chemical Biology & Drug Design 77 (1): 1–11. (January 2011). doi:10.1111/j.1747-0285.2010.01054.x. PMID 21118377.

ncbi.nlm.nih.gov

“AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance”. Cancer Cell 16 (5): 401–12. (November 2009). doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.

pmc.ncbi.nlm.nih.gov

“AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance”. Cancer Cell 16 (5): 401–12. (November 2009). doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.

nytimes.com

Grady D (2013年10月31日). “Serious Danger of Blood Clots Halts Sale of Leukemia Drug”. Business. New York Times. 2021年9月18日閲覧。

onclive.com

“FDA Grants Ponatinib Full Approval for Rare Leukemias”. 2021年9月18日閲覧。

otsuka.co.jp

“大塚製薬白血病治療薬として「ポナチニブ」を国内製造販売承認申請｜ニュースリリース｜大塚製薬”. 大塚製薬株式会社　Otsuka Pharmaceutical. 2021年9月18日閲覧。
“白血病治療薬「アイクルシグ®錠15㎎」国内製造販売承認を取得｜ニュースリリース｜大塚製薬”. 大塚製薬株式会社　Otsuka Pharmaceutical. 2021年9月18日閲覧。

pmda.go.jp

info.pmda.go.jp

“アイクルシグ錠15mg”. www.info.pmda.go.jp. 2021年9月18日閲覧。